Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study

Next Previous
Trial Profile

Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vinorelbine (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms GILT
  • Sponsors Pierre Fabre

Most Recent Events

  • 01 Oct 2021 Results retrospectively analysing pre-therapeutic FFPE tumour tissue from patients enrolled in the GILT trial and assessing prognostic role of PD-L1 and TiLs in locally advanced NSCLC, published in the Lung Cancer
  • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
  • 08 Oct 2010 Preliminary results have been presented at the 35th Congress of the European Society for Medical Oncology (ESMO).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top